Jover Placid 4

What Happened
Jover Placid, Executive Vice President and Chief Human Resources Officer of Teva Pharmaceutical Industries (TEVA), had 14,150 restricted share units vest on March 5, 2026. Those RSUs were converted to ordinary shares and immediately sold in the open market the same day, generating approximately $448,108 in proceeds (weighted average sale price $31.67).

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (filed within the two-business-day deadline).
• Sale: 14,150 shares sold in multiple trades at a weighted average price of $31.67 (range $31.26–$32.34). Proceeds ≈ $448,108.
• Derivative/vesting: 14,150 RSUs vested and were converted to shares (reported as exercise/conversion of derivative). The filing indicates the shares vested were sold, including shares sold to cover tax withholding.
• Plan/authorization: Sale executed pursuant to a Rule 10b5-1 trading plan adopted Nov 10, 2025.
• Shares owned after transaction: Not specified in this filing.
• Other notes: Ordinary shares may be represented by American Depositary Shares (ADS); RSU grant and vesting schedule referenced in the filing.

Context
This was a routine sale following RSU vesting and conversion, not a discretionary open-market purchase. The RSUs were granted previously (series with equal tranches vesting annually through 2029), and the filing shows the vested shares were converted and sold immediately—effectively a cashless settlement to realize value and cover tax obligations. The use of a 10b5-1 plan indicates the sales were pre-planned rather than ad hoc.